Research programme: antibacterials - Actelion

Drug Profile

Research programme: antibacterials - Actelion

Alternative Names: AB-1; AB-2; AB-3; Actelion-10; Actelion-11; Actelion-9; Injectable antibacterials - Actelion; Oral antibacterials - Actelion

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Actelion Pharmaceuticals
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Bacterial infections; Nosocomial infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Bacterial-infections in Switzerland (Injection)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Bacterial-infections in Switzerland (PO)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Nosocomial-infections in Switzerland (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top